Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN).

The international journal of biochemistry & cell biology - 1 Aug 2022

Glück Madeleine, Dally Lina, Jücker Manfred, Ehm Patrick

Abstract excerpt

BACKGROUND: Myeloproliferative neoplasms (MPN) are a group of chronic haematological disorders. At the molecular level of MPN cells, the gain-of-function mutation V617F of the Janus kinase 2 (JAK2) leads to a constitutive activation of the downstream signaling cascade and is a conventional criteria for diagnosis. Here, the functional role of the tumor suppressor SHIP1 (SH2 domain containing inositol-5 phosphatase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinase 2
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Neoplasms

Share to Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases

Share to Proto-Oncogene Proteins c-akt

Share to Signal Transduction

Source

Identifiers

PMID: 35609769
DOI: 10.1016/j.biocel.2022.106229

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN).PMID 35609769Read ↗

Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesisSemantic proximity Read ↗

Nuclear accumulation of SHIP1 mutants derived from AML patients leads to increased proliferation of leukemic cells.Semantic proximity Read ↗

PITPβ Drives JAK2 V617F-Mediated Myeloproliferative Neoplasms by Promoting PtdIns(3,4)P <sub>₂</sub> -Dependent AKT HyperactivationSemantic proximity Read ↗

Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia.Semantic proximity Read ↗

Mutation analysis of SHIP gene in acute leukemia.Semantic proximity Read ↗

Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.Semantic proximity Read ↗

BCR/ABL Directly Inhibits Expression of SHIP, an SH2-Containing Polyinositol-5-Phosphatase Involved in the Regulation of HematopoiesisSemantic proximity Read ↗

Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells.Semantic proximity Read ↗

Ph(-) myeloproliferative neoplasm red blood cells display deregulation of IQGAP1-Rho GTPase signaling depending on CALR/JAK2 status.Semantic proximity Read ↗

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasmsSemantic proximity Read ↗

[Mutation analysis of SHIP gene in acute leukemia].Semantic proximity Read ↗

Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.